Experiments

Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).

Publications 1.3k Datasets 392.5k Experiments 14

System / cell line: paraffin ✕ Assay: clinical ✕ Clear

A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations.

PMID 17047648 · PMC2360715 · British journal of cancer · 2006 · 7 claims · 5 setups

Full-text index only

Gefitinib is highly active and well tolerated as first-line therapy for advanced NSCLC with EGFR mutations

paraffin-embedded patients same direct phase kaplan-meier
A spectrum of severe familial liver disorders associate with telomerase mutations.

PMID 19936245 · PMC2775683 · PloS one · 2009 · 7 claims · 8 setups

Full-text index only

Heterozygous telomerase loss-of-function mutations associate with, but are not deterministic of, a broad spectrum of hematologic and severe liver abnormalities.

leukocyte leukocytes reconstitution liver sanger flow telomerase
Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status.

PMID 9703286 · PMC2063030 · British journal of cancer · 1998 · 6 claims · 4 setups

Full-text index only

Paclitaxel/cisplatin therapy produces a higher positive response rate than cyclophosphamide/cisplatin therapy in advanced ovarian cancer

patients frozen genomic clinically randomized rt-pcr temporal
Mutant, wild type, or overall p53 expression: freedom from clinical progression in tumours of astrocytic lineage.

PMID 15494720 · PMC2409947 · British journal of cancer · 2004 · 8 claims · 7 setups

Full-text index only

Significant overexpression of p53 protein was found in 48% of 74 astrocytic tumours

archival subset recombinant same immunohistochemistry antibody cytokeratin
Genetic alterations in the coding region of the bak gene in uterine cervical carcinoma.

PMID 12771926 · PMC2377111 · British journal of cancer · 2003 · 8 claims · 3 setups

Full-text index only

A significant frequency of mutations (six missense, one silent) was found in the coding region of the bak gene (exons 3, 4, 6) in uterine cervical carcinoma

uterine non-neoplastic stage pcr-sscp clinical
Prognostic significance of p53 and ras gene abnormalities in lung adenocarcinoma patients with stage I disease after curative resection.

PMID 7852188 · PMC5919395 · Japanese journal of cancer research : Gann · 1994 · 6 claims · 5 setups

Full-text index only

Presence of p53 gene abnormalities is associated with shorter disease-free survival in stage I lung adenocarcinoma

formalin-fixed stage pcr-dgge immunohistochemistry pcr-rflp
Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients.

PMID 17626639 · PMC1952070 · BMC cancer · 2007 · 7 claims · 4 setups

Full-text index only

EGFR mutations (exon 19 deletions, exon 21 L858R) did not correlate with gefitinib response in this cohort

microdissected formalin-fixed archival clinical pcr fluorescence laser
Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?

PMID 17595663 · PMC2360307 · British journal of cancer · 2007 · 8 claims · 14 setups

Full-text index only

A SNP in the cytidine deaminase (CDA) gene (208G>A, haplotype *3) decreases gemcitabine clearance, increases Cmax/AUC, and increases neutropenia risk when gemcitabine is combined with platinum drugs or 5-FU

japanese paraffin-embedded tumour recombinant prospective immunohistochemistry pcr
Expression of p73, a novel protein related to the p53 tumour suppressor p53, and apoptosis in cholangiocellular carcinoma of the liver.

PMID 10362118 · PMC2363034 · British journal of cancer · 1999 · 7 claims · 6 setups

Full-text index only

p73 protein is expressed (nuclear immunostaining) in a substantial subset of cholangiocellular carcinomas

cholangiocellular ccc lysates immunohistochemistry direct western
No significant role for beta tubulin mutations and mismatch repair defects in ovarian cancer resistance to paclitaxel/cisplatin.

PMID 16095531 · PMC1199587 · BMC cancer · 2005 · 6 claims · 4 setups

Full-text index only

TUBB exon 4 mutations are not found in primary ovarian carcinomas treated with paclitaxel/cisplatin

ovarian same pcr agarose microsatellite
Comprehensive analysis of metastatic gastric cancer tumour cells using single-cell RNA-seq.

PMID 33441952 · PMC7806779 · Scientific reports · 2021 · 8 claims · 5 setups

Has reproduction · 47

CDK12, ERBB2, and CLDN11 are overexpressed in metastatic lymph node gastric cancer and serve as candidate lymph node metastasis marker genes.

tumour gastric qc-passed single-cell immunofluorescence immunohistochemistry
Abnormalities of the p53 MDM2 and DCC genes in human leiomyosarcomas.

PMID 8198970 · PMC1969417 · British journal of cancer · 1994 · 6 claims · 8 setups

Full-text index only

A significant minority of leiomyosarcomas harbor p53 gene point mutations or deletions

leiomyosarcomas frozen leiomyosarcoma sarcoma sscp direct immunohistochemistry
Chromosome alterations and E-cadherin gene mutations in human lobular breast cancer.

PMID 10584868 · PMC2374316 · British journal of cancer · 1999 · 8 claims · 5 setups

Full-text index only

LOH at chromosome 16q21-q22.1 occurs in 100% of informative lobular breast tumours, the highest frequency of any region tested

lobular pcr loh loh pcr-sscp sequencing
Convergence of mutation and epigenetic alterations identifies common genes in cancer that predict for poor prognosis.

PMID 18507500 · PMC2429944 · PLoS medicine · 2008 · 7 claims · 7 setups

Full-text index only

At least 36 of the 189 newly mutated CAN genes are targets of promoter CpG island hypermethylation, often in both colon and breast cancer cell lines

breast same selected hct116 expression methylation-specific rt-pcr

Experiments

A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations.

A spectrum of severe familial liver disorders associate with telomerase mutations.

Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status.

Mutant, wild type, or overall p53 expression: freedom from clinical progression in tumours of astrocytic lineage.

Genetic alterations in the coding region of the bak gene in uterine cervical carcinoma.

Prognostic significance of p53 and ras gene abnormalities in lung adenocarcinoma patients with stage I disease after curative resection.

Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients.

Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?

Expression of p73, a novel protein related to the p53 tumour suppressor p53, and apoptosis in cholangiocellular carcinoma of the liver.

No significant role for beta tubulin mutations and mismatch repair defects in ovarian cancer resistance to paclitaxel/cisplatin.

Comprehensive analysis of metastatic gastric cancer tumour cells using single-cell RNA-seq.

Abnormalities of the p53 MDM2 and DCC genes in human leiomyosarcomas.

Chromosome alterations and E-cadherin gene mutations in human lobular breast cancer.

Convergence of mutation and epigenetic alterations identifies common genes in cancer that predict for poor prognosis.